Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-ND 4.0Neurology

Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women

4 more authors
17 affiliations
  1. 1Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
  2. 2Department of Neurology, Yale University School of Medicine, New Haven, CT
  3. 3Cátedra DeCo MICOF-CEU UCH, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia, Spain
  4. 4Division of Neuroinmunology, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
  5. 5Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
  6. 6Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA
  7. 7Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, United Kingdom
  8. 8Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
  9. 9Department of Neuropsychiatry, Sahlgrenska University Hospital, Region Västra Götaland, Mölndal, Sweden
  10. 10Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg, Sweden
  11. 11Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, the Netherlands
  12. 12Amsterdam Neuroscience, Neurodegeneration, the Netherlands
  13. 13Genomics of Neurodegenerative Diseases and Aging, Department of Human Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands
  14. 14Faculty of Medicine, University of Ljubljana, Slovenia
  15. 15Department of Radiology, Stanford University Hospital, Palo Alto, CA
  16. 16Department of Radiology, The Institution for Clinical Neuroscience, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden ; and
  17. 17Melbourne School of Psychological Science, University of Melbourne, Australia .

Abstract

Background and Objectives: Women are disproportionately affected by Alzheimer disease (AD), a vulnerability that may relate to estrogen fluctuations across the lifespan. Estrogen has neuroprotective and vasoprotective effects, suggesting that lifetime estrogen exposure may influence both AD-related neurodegeneration and cerebrovascular health. However, its association with late-life vascular and neurodegenerative brain changes remains unclear. We aimed to examine the associations of lifelong estrogen exposure—endogenous (reproductive span) and exogenous (oral contraceptives [OCs], menopausal hormone therapy [MHT])—with late-life vascular brain injury and AD-related atrophy and explore apolipoprotein-ε4 (APOE-ε4) effects.

Methods: This population-based study included cognitively unimpaired women from the Gothenburg H70-1944 Birth Cohort who underwent brain MRI at age 70 and again 5 years later. Reproductive lifespan was calculated as age at menopause or oophorectomy minus age at menarche. OC and MHT use were categorized as ever vs never users. Outcomes included cerebral small vessel disease (SVD), AD-related cortical thickness, and white matter integrity (fractional anisotropy). SVD burden was a composite score derived from white matter hyperintensities (WMHs), lacunes, cerebral microbleeds (CMBs), and perivascular spaces (PVSs) (range 0–4). Linear, multinomial, and mixed-effects regression models were adjusted for relevant confounders and stratified by APOE-ε4.

Results: Among 352 women (mean age 70 years), longer reproductive span was associated with lower SVD burden (OR = 0.92, 95% CI 0.86–0.99). MHT use was associated with fewer PVSs and CMBs. OC and MHT use were associated with greater white matter integrity, with combined use showing the highest fractional anisotropy compared with nonusers (β = 0.45, 95% CI 0.12–0.78). No multiplicative interaction between OCs and MHT was observed, although joint exposure analyses suggested cumulative effects. MHT use was associated with greater AD-related cortical thickness among APOE-ε4 carriers only (β = 0.38, 95% CI 0.01–0.76). Longer estrogen exposure was associated with stable cortical thickness and WMH trajectories over time.

Discussion: Greater lifetime estrogen exposure, both endogenous and exogenous, was associated with lower cerebrovascular pathology in women and, among APOE-ε4 carriers, greater cortical thickness in AD-vulnerable regions. These findings support the potential role of cerebrovascular mechanisms linking estrogen exposure to brain aging. Limitations included observational design and self-reported, binary estrogen exposure. Potential cognitive effects require further studies.

Related

  1. Editorial: Hormonal responses in women across the lifespan and their impact on physical performance
    Eduardo Piedrafita, César Berzosa, Marta Sofía Valero +1
    Frontiers in EndocrinologyPeer-reviewedCC BY 4.0Endocrinology & metabolismCrossref
  2. Hormonal Effects during the Reproductive Years on Brain and Behavior: Molecular Discovery to Promising Therapeutics for Women’s Mental Health
    S. Andrea Wijtenburg, Rebecca Shansky, Julia Sacher +7
    The Journal of NeurosciencePeer-reviewedPublisher termsFull textEpidemiology & public healthPMC
  3. Nutritional Epigenetics Across the Female Lifespan: From Developmental Programming to Reproductive Health and Healthy Aging
    Sofoklis Stavros, Anastasios Potiris, Athanasios Zikopoulos +8
    NutrientsPeer-reviewedCC BY 4.0NutritionCrossref
  4. BMP4 and WIF1 expression in mother–child pairs in relation to anorectal malformations and maternal reproductive history
    Maleha Asim, Amena Rahim, Mudassar Fiaz +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaCrossref
  5. Does the use of hormonal contraceptives induce negative metacognitions, brooding, and depressive symptoms in an adolescent community sample?
    Leif Edward Ottesen Kennair, Marius Stavang, Ingrid Grønnæss +5
    Comprehensive psychoneuroendocrinologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
BibTeX
@article{lorenzon2026reproductive,
  title = {{Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women}},
  author = {Giulia Lorenzon and Gemma Garcia-Lluch and Gillian T. Coughlan and Shireen Sindi and Silvia Maioli and Konstantinos Poulakis and Jenna Najar and Rosaleena Mohanty and Lina Rydén and Ernest Privsek and Sara Shams and Silke Kern and Rachel F. Buckley and Eric Westman and Ingmar Skoog and Anna Marseglia},
  journal = {Neurology},
  year = {2026},
  month = nov,
  doi = {10.1212/wnl.0000000000218706},
  url = {https://doi.org/10.1212/wnl.0000000000218706},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Reproductive Lifespan and Hormonal Therapy in Relation to Later-Life Neurovascular Health in Community-Dwelling Older Women
AU  - Giulia Lorenzon
AU  - Gemma Garcia-Lluch
AU  - Gillian T. Coughlan
AU  - Shireen Sindi
AU  - Silvia Maioli
AU  - Konstantinos Poulakis
AU  - Jenna Najar
AU  - Rosaleena Mohanty
AU  - Lina Rydén
AU  - Ernest Privsek
AU  - Sara Shams
AU  - Silke Kern
AU  - Rachel F. Buckley
AU  - Eric Westman
AU  - Ingmar Skoog
AU  - Anna Marseglia
PY  - 2026
DA  - 2026/11/04
JO  - Neurology
DO  - 10.1212/wnl.0000000000218706
UR  - https://doi.org/10.1212/wnl.0000000000218706
AB  - Background and Objectives: Women are disproportionately affected by Alzheimer disease (AD), a vulnerability that may relate to estrogen fluctuations across the lifespan. Estrogen has neuroprotective and vasoprotective effects, suggesting that lifetime estrogen exposure may influence both AD-related neurodegeneration and cerebrovascular health. However, its association with late-life vascular and neurodegenerative brain changes remains unclear. We aimed to examine the associations of lifelong estrogen exposure—endogenous (reproductive span) and exogenous (oral contraceptives [OCs], menopausal hormone therapy [MHT])—with late-life vascular brain injury and AD-related atrophy and explore apolipoprotein-ε4 (APOE-ε4) effects.  Methods: This population-based study included cognitively unimpaired women from the Gothenburg H70-1944 Birth Cohort who underwent brain MRI at age 70 and again 5 years later. Reproductive lifespan was calculated as age at menopause or oophorectomy minus age at menarche. OC and MHT use were categorized as ever vs never users. Outcomes included cerebral small vessel disease (SVD), AD-related cortical thickness, and white matter integrity (fractional anisotropy). SVD burden was a composite score derived from white matter hyperintensities (WMHs), lacunes, cerebral microbleeds (CMBs), and perivascular spaces (PVSs) (range 0–4). Linear, multinomial, and mixed-effects regression models were adjusted for relevant confounders and stratified by APOE-ε4.  Results: Among 352 women (mean age 70 years), longer reproductive span was associated with lower SVD burden (OR = 0.92, 95% CI 0.86–0.99). MHT use was associated with fewer PVSs and CMBs. OC and MHT use were associated with greater white matter integrity, with combined use showing the highest fractional anisotropy compared with nonusers (β = 0.45, 95% CI 0.12–0.78). No multiplicative interaction between OCs and MHT was observed, although joint exposure analyses suggested cumulative effects. MHT use was associated with greater AD-related cortical thickness among APOE-ε4 carriers only (β = 0.38, 95% CI 0.01–0.76). Longer estrogen exposure was associated with stable cortical thickness and WMH trajectories over time.  Discussion: Greater lifetime estrogen exposure, both endogenous and exogenous, was associated with lower cerebrovascular pathology in women and, among APOE-ε4 carriers, greater cortical thickness in AD-vulnerable regions. These findings support the potential role of cerebrovascular mechanisms linking estrogen exposure to brain aging. Limitations included observational design and self-reported, binary estrogen exposure. Potential cognitive effects require further studies.
SN  - 0028-3878
SN  - 1526-632X
ER  -